BEIJING, Oct. 09, 2017 (GLOBE NEWSWIRE) -- C-Bridge Capital, a private equity firm focused on development and late-stage investment opportunities within the growing Chinese health care market, announced today the appointment of several highly seasoned healthcare and investment professionals to key leadership roles, including Abbas Hussain who joins the firm as Senior Partner.
Abbas Hussain has more than 25 years of deep industry expertise, serving in business leadership roles around the world at Eli Lilly and Company, and most recently at GlaxoSmithKline as Global President, Pharmaceuticals and Vaccines where he led operations in U.S., Europe, Emerging Markets and Asia. During Abbas’ time at GlaxoSmithKline, he also was a member of the Corporate Executive Team, a Non-Executive Director of ViiV Healthcare, a member of Aspen Pharma care board (the largest South African pharmaceutical company), and he was on the board of the Duke and National University of Singapore Medical school.
“We are thrilled to have Abbas join our global team at C-Bridge Capital, as he brings an impressive track record of profitable growth across unique and diverse markets,” said Fu Wei, Chief Executive Officer of C- Bridge Capital. “Abbas is a valuable addition to our team, which is focused on identifying emerging industry leaders across biotechnology, pharmaceuticals, medical devices, and in vitro diagnostics to bring global innovation into China.”
In addition, the Company over the last year welcomed four new appointees into senior leadership roles in the U.S., all managing directors who will lead offices in New York, Boston and San Diego, increasing the firm’s capacity to form strategic partnerships across borders.
“Each of these individuals brings an important set of expertise and deep industry insights to C-Bridge Capital, helping us to invest strategically in the rapidly growing Chinese health care market, as well as grow these important scientific innovations across international borders, bringing them to patients in need,” commented Fu.
These key appointments include:
- Sean Cao, PhD, a 20-year veteran of the pharmaceutical sector joined as Managing Director in the Boston office in October 2016. Previously he was Vice President of Global Business Development at Simcere Pharmaceutical Group and President and Board of Directors at Simcere of America. Prior to that, he was Senior Director at Sanofi leading the externalization effort in global research and development.
- Jason Brown, PhD, joined as Managing Director in the San Diego office in October 2016 and brought more than 17 years in healthcare investing and biopharmaceutical research and development to the firm. Jason was previously a partner at Thomas, McNerney & Partners, where he served as a member of the investment team and was a board member or observer for several portfolio companies.
- Michael Keyoung, MD, PhD, joins as Managing Director and head of North America in the new New York City office, bringing with him more than 20 years of experience as a physician, investor and healthcare executive. Previously he was President and CEO of Genexine Inc., a biotechnology company developing biologics across immuno-oncology, metabolic and autoimmune diseases. In addition, Michael has served in several C-Suite and strategic consulting positions at other healthcare investment firms and global biotechnology companies, including Eli Lilly and Company, UCB and Samsung Biologics.
- Zhang Tong, PhD, joins as Managing Director in the New York City office, bringing with him more than 20 years of healthcare experience spanning corporate, investment and research roles. Most recently Zhang was Head of Corporate Business Development at Wuxi AppTec in Shanghai, where he led strategic partnerships for biopharmaceuticals, medical devices, diagnostics and genomics. Prior to that he oversaw executive partnership programs as part of the leadership teams at MSD China, Merck & Co. and EKR Therapeutics. He also spent the earlier part of his career in investment banking at ESP Equity Partners and Credit Suisse.
About C-Bridge Capital
C-Bridge Capital is a healthcare dedicated private equity firm, focused on growth and late stage investment opportunities with US$700 million of Assets Under Management. C-Bridge Capital’s current portfolio includes China’s leading players in pharmaceuticals, medical devices, diagnostics and healthcare services. C-Bridge Capital is committed to support commercialization of cutting edge technologies and companies that fulfill unmet medical needs, thus continuously improving the standard and quality of care for patients.